Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

136
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
136
Obesity01:24

Obesity

1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

147
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
147
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

202
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
202
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

173
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
173
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

460
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
460

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of machine-learning algorithms to identify the key determinants of risk for HIV, hepatitis C and hepatitis B in primary care settings.

BMC infectious diseases·2026
Same author

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The lancet. Gastroenterology & hepatology·2026
Same author

Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023.

eGastroenterology·2026
Same author

Cardiovascular risk in MASLD: What multiple lines of evidence reveal.

Journal of hepatology·2026
Same author

Doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis-leave no one behind: author's reply.

The Lancet regional health. Europe·2026
Same author

Real-world evidence in metabolic dysfunction-associated steatotic liver disease (MASLD): insights, challenges, and future directions.

The Lancet regional health. Europe·2026

Related Experiment Video

Updated: Jan 2, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.3K

Obesity Predicts Liver Function Testing and Abnormal Liver Results.

Wenhao Li1, Kate Homer2, Sally Hull2

  • 1Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.

Obesity (Silver Spring, Md.)
|December 6, 2019
PubMed
Summary

Obesity predicts liver testing and abnormal results in young people, but not in children. A coordinated strategy is needed for liver testing in this population due to rising metabolic dysfunction.

More Related Videos

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.6K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.7K

Related Experiment Videos

Last Updated: Jan 2, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.3K
Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.6K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.7K

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Public Health

Background:

  • Abnormal liver function tests in children and young people (CYP) are linked to future adult liver disease, particularly with obesity.
  • Obesity and metabolic risk factors are increasing in CYP, raising concerns about liver health.

Purpose of the Study:

  • To investigate if obesity and metabolic risk factors predict liver function testing and abnormal liver test results in CYP.
  • To analyze the relationship between body mass index (BMI) and alanine aminotransferase (ALT) testing and results in a large CYP population.

Main Methods:

  • Retrospective cross-sectional population study utilizing electronic health records of 257,746 CYP aged 10-25 years in London, UK.
  • Extracted demographic and clinical data, including serum ALT tests from 2015-2017.
  • Adjusted BMI category thresholds for age and ethnicity; performed multivariate analyses.

Main Results:

  • 14% of CYP had ALT measured, with 5.4% showing abnormal results; 36.3% were overweight or obese.
  • Nonalcoholic fatty liver disease was the most frequent liver diagnosis.
  • Overweight/obesity independently predicted ALT testing in young people (18-25) but not children (10-17), and predicted abnormal ALT results across all CYP.

Conclusions:

  • Overweight and obesity are significant predictors of liver testing and abnormal results in young people, regardless of ALT threshold.
  • The rising prevalence of metabolic dysfunction necessitates a strategic approach to liver testing and result interpretation in CYP.
  • Early identification and intervention for liver issues in obese youth are crucial for preventing long-term disease burden.